| Entry |
|
|---|
| Name |
Pramipexole (USAN/INN) |
|---|
| Formula |
C10H17N3S
|
|---|
| Exact mass |
211.1143
|
|---|
| Mol weight |
211.3271
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01472 Dopamine agonist
DG01967 Antiparkinson agent
|
|---|
| Remark |
| Product (DG00863): | D00559<JP/US> |
|
|---|
| Efficacy |
Antiparkinsonian, Antidepressant, Dopamine receptor agonist |
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07213 | Dopamine receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N04 ANTI-PARKINSON DRUGS
N04B DOPAMINERGIC AGENTS
N04BC Dopamine agonists
N04BC05 Pramipexole
D05575 Pramipexole (USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01472 Dopamine agonist
DG00863 Pramipexole
D05575 Pramipexole
DG01967 Antiparkinson agent
DG00863 Pramipexole
D05575 Pramipexole
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D05575 Pramipexole (USAN/INN)
DRD3
D05575 Pramipexole (USAN/INN)
DRD4
D05575 Pramipexole (USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01472 Dopamine agonist
DG00863 Pramipexole
DG01967 Antiparkinson agent
DG00863 Pramipexole
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 14
1 C8y C 21.1335 -18.9431
2 C8y C 21.1744 -17.5455
3 N5x N 22.5777 -19.3681
4 C1x C 20.0330 -19.6475
5 C1x C 20.0274 -16.8467
6 S2x S 22.5720 -17.1086
7 C8y C 23.3987 -18.2384
8 C1x C 18.8276 -18.9548
9 C1y C 18.8219 -17.5513
10 N1a N 24.8023 -18.2793
11 N1b N 17.6048 -16.8524
12 C1b C 16.3936 -17.5572
13 C1b C 15.1884 -16.8583
14 C1a C 13.9771 -17.5629
BOND 15
1 1 2 2
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 2
7 4 8 1
8 5 9 1
9 7 10 1
10 9 11 1 #Down
11 11 12 1
12 12 13 1
13 13 14 1
14 6 7 1
15 8 9 1
|
|---|
